Body Composition (DEXA, Visceral Fat) - References

Body Composition (DEXA, Visceral Fat) — Literature Dossier

Navigation

• Backed Topic Note: Body Composition (DEXA, Visceral Fat)
• References Hub: 03 - Diagnostics & Quantified Self References MOC
• Parent Silo MOC: 03 - Diagnostics & Quantified Self MOC

---

Landmark Peer-Reviewed Studies

1. Srikanthan & Karlamangla (2014) — Muscle Mass Index as a Predictor of Longevity in Older Adults

• Citation: Srikanthan, P., & Karlamangla, A. S. (2014). Muscle mass index as a predictor of longevity in older adults. The American Journal of Medicine, 127(6), 547–553.
• Identifiers: DOI: 10.1016/j.amjmed.2014.02.007 (DOI · SciDB · Scholar) | PMID: 24561114 (PubMed · Europe PMC) | PMCID: PMC4037311 (PMC Full Text)
• Study Design & Cohort: Prospective 12–18 year survival analysis of NHANES III participants aged $\ge 55$ in men and $\ge 65$ in women ($N=3,659$).
• Quantitative Findings & Diagnostic Thresholds:
  • All-cause mortality was significantly lower in the highest quartile of Muscle Mass Index compared to the lowest quartile (Adjusted Rate Ratio $0.80$, $95\%\text{ CI }0.66–0.97,p=0.02$) even after adjusting for central obesity, HOMA-IR, hs-CRP, and chronic comorbidities, proving skeletal muscle mass is an independent determinant of human survival.

2. Kuk et al. (2006) — Visceral Fat Is an Independent Predictor of All-Cause Mortality in Men

• Citation: Kuk, J. L., Katzmarzyk, P. T., Nichaman, M. Z., Church, T. S., Blair, S. N., & Ross, R. (2006). Visceral fat is an independent predictor of all-cause mortality in men. Obesity, 14(2), 336–341.
• Identifiers: DOI: 10.1038/oby.2006.43 (DOI · SciDB · Scholar) | PMID: 16571861 (PubMed · Europe PMC)
• Study Design & Cohort: Prospective imaging cohort ($N=291$ men undergoing direct L4–L5 abdominal computed tomography quantification of Visceral Fat, Subcutaneous Fat, and Liver Fat, followed for $9.7\pm 2.3\text{ years}$).
• Quantitative Findings & Diagnostic Thresholds:
  • Visceral fat mass was a powerful independent predictor of all-cause mortality ($\text{OR }1.83$ per 1-SD increase, $95\%\text{ CI }1.23–2.73$; and $\text{HR }1.98$ after controlling for subcutaneous fat and liver fat), whereas abdominal subcutaneous fat was not associated with mortality ($\text{OR }0.90$), confirming that metabolic toxicity resides specifically in the intra-abdominal visceral compartment.

3. Falutz et al. (2007) & Stanley et al. (2014) — Effects of Tesamorelin (GHRH Analog) on Visceral Fat and Hepatic Lipid

• Citation: Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., … & Grinspoon, S. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. (Paired with Stanley, T. L., et al. [2014], The Lancet HIV, 1[1], e42–e51).
• Identifiers: DOI: 10.1056/NEJMoa072375 (DOI · SciDB · Scholar) | PMID: 18057338 (PubMed · Europe PMC) (and DOI: 10.1016/S2352-3018(14)70016-X (DOI · SciDB · Scholar) | PMID: 26421232 (PubMed · Europe PMC))
• Study Design & Cohort: Phase 3 multicenter randomized, double-blind, placebo-controlled trial ($N=412$ patients with excess abdominal visceral fat randomized $2:1$ to $2\text{ mg/day}$ SC Tesamorelin vs. placebo for 26 weeks) plus 6-month magnetic resonance spectroscopy hepatic fat RCT ($N=50$).
• Quantitative Findings & Diagnostic Thresholds:
  • Tesamorelin decreased Visceral Adipose Tissue (VAT) area by $-15.2\%$ ($-27.8{\text{ cm}}^2$) vs. $+5.0\%$ on placebo ($p<0.001$; net $-20\%$ treatment effect), increased trunk lean muscle mass by $+1.35\text{ kg}$ ($p<0.001$), reduced Triglycerides by $-50\text{ mg/dL}$ ($p<0.001$), and reduced intrahepatic fat by $-37\%$ ($p=0.02$) while preserving subcutaneous limb fat.

4. Watson et al. (2018) — High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function (The LIFTMOR Randomized Controlled Trial)

• Citation: Watson, S. L., Weeks, B. K., Weis, L. J., Harding, A. T., Horan, S. A., & Beck, B. R. (2018). High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. Journal of Bone and Mineral Research, 33(2), 211–220.
• Identifiers: DOI: 10.1002/jbmr.3284 (DOI · SciDB · Scholar) | PMID: 28975661 (PubMed · Europe PMC)
• Study Design & Cohort: 8-month single-blind randomized controlled trial ($N=101$ postmenopausal women with low bone mass [T-score $<-1.0$] randomized to $2\times 30\text{ min/week}$ supervised High-Intensity Resistance and Impact Training [HiRIT: $5\times 5$ deadlifts, overhead press, back squats at $>80–85\%\text{ 1RM}$ + impact drop landings] vs. low-intensity home exercise control).
• Quantitative Findings & Diagnostic Thresholds:
  • HiRIT significantly increased Lumbar Spine BMD by $+2.9\pm 2.8\%$ vs. $-1.2\pm 2.8\%$ in controls ($p<0.001$), increased Femoral Neck BMD by $+0.3\%$ vs. $-1.9\%$ ($p=0.004$), and increased Femoral Neck cortical thickness by $+13.6\%$ ($p=0.014$) with zero fractures or adverse events ($92\%$ adherence).